Rowe, KA1, Tesoriero, JM1, Davis, SJ1, Heavner, KK1, Rothman, J2,

Slides:



Advertisements
Similar presentations
Utilization of Integrated Hepatitis Services Among People with a History of Injection Drug Use in an STD Clinic 2004 National STD Prevention Conference.
Advertisements

Perspectives on Outreach from the NYC Department of Health and Mental Hygiene Benjamin Tsoi, MD, MPH Bureau of HIV/AIDS Prevention and Control NYC Department.
Impact of Age and Race on New HIV Infections among Men who have Sex with Men in Los Angeles County Shoshanna Nakelsky, MPH Division of HIV and.
Delay from Testing HIV Positive until First HIV Care for Drug Users: Adverse Consequences and Possible Solutions Barbara J Turner MD, MSEd* John Fleishman.
Evaluating the Impact of Integrating Viral Hepatitis Services for HIV and STD Prevention Moderator: Danni Lentine.
Hepatitis and Liver Cancer A National Strategy for Prevention and Control of Hepatitis B and C.
Enhancing HIV/AIDS Surveillance in California California Department of Public Health Office of AIDS Guide for Health Care Providers.
Incorporating HIV and Viral Hepatitis Testing and Referral into Idaho Drug Court Programs Presented by Idaho Advisory Council on HIV and AIDS, Bebe Thompson,
Midwest AIDS Training & Education Center Health Care Education & Training, Inc. HIV/AIDS Case-Finding In Family Planning Clinics.
Afghanistan’s Present IDUs-HIV/AIDS Situation and future action plan Dr.Saifur-Rehman NACP Director April,11,2007 Islamic Republic of Afghanistan Ministry.
HIV Infection Among Those with an Injection Drug Use*- Associated Risk, Florida, 2012 Florida Department of Health HIV/AIDS and Hepatitis Section Division.
A Webinar Hosted by The National Harm Reduction Coalition The National Black Leadership Commission on AIDS The Coalition for Positive Health Empowerment.
HIV/STD Epidemiology in Oklahoma HIV/STD Service Division of Prevention and Preparedness Oklahoma State Department of Health.
Wisconsin Department of Health Services HIV/AIDS Surveillance Annual Review New diagnoses, prevalent cases, and deaths through December 31, 2013 April.
ABSTRACT Introduction: HIV infection is growing relatively fast among seniors. Among the clinical implications are that older patients have less ability.
Preventing Medical Complications of Injection Drug Use Keith Heinzerling, MD, MPH UCLA Seminars in Addiction Psychiatry Course August 11, 2005.
Olivia Chang, MPH Research and Program Manager Pangaea Global AIDS
Pennsylvania: The State of HCV 2015
Need for vaccination for vaccine preventable hepatitis in methadone maintenance treatment Randy Seewald, MD 1,2,3, Eli Kamara, BS 2, Ruy Tio, DO 1,2, Rashiah.
California Department of Public Health Office of AIDS HIV CARE and PREVENTION 2009: You Need to Know.
Co-infections of Hepatitis C or Tuberculosis Among Persons Living with HIV in The Florida Cohort Project Alexander Zirulnik MPH, Chukwuemeka Okafor MPH,
Association for Women in Psychology Conference “A Model of Integrated Treatment for Women with Co-Occurring Disorders who are at High Risk for HIV” Presented.
Housing Status and HIV Risk Behaviors Among Homeless and Housed Persons with HIV in the United States The findings and conclusions in this presentation.
Organizing Drug Users for Public Health Policy Changes 17 th International Conference on the Reduction of Drug Related Harm Jason Farrell, Executive Director.
| Web: The findings and conclusions in this report are those of the authors and do not necessarily represent the official.
Non-Medical Staff Knowledge, Beliefs and Practices about HIV and Hepatitis for Injection Drug Users Rowe, KA 1, Tesoriero, JM 1, Heavner, KK 1, Rothman,
Adult Hepatitis A and B Vaccination in Traditional and Non-Traditional Sites, North Carolina Beth Rowe-West, Head Immunization Branch Division of Public.
PREVENTION OF INFECTIOUS DISEASES IN PRISONS Recent Experience from Portugal Henrique Barros Ministério da Saúde.
HIV/AIDS in Utah Edwin Espinel HIV Counseling & Testing, Partner Services Program Coordinator University of Utah May 2013 Utah Department of Health Bureau.
Seeking HIV-testing Only: Missed Opportunity for HIV Prevention?
Hepatitis C Virus Program in Chicago
1University of Kentucky, Lexington, Kentucky
Bloodborne viral and sexually transmissible infections in Aboriginal and Torres Strait Islander people: Annual Surveillance Report 2016.
Pengjun Lu, PhD, MPH;1 Kathy Byrd, MD, MPH;2
Integrating Hepatitis into the World of Community Planning
US Census Data Ortman, Jennifer M., Victoria A. Velkoff, and Howard Hogan. An Aging Nation: The Older Population in the United States, Current Population.
Hepatitis C Allies of Philadelphia August 2, 2017
The potential for selection and misclassification bias when sampling men who have sex with men (MSM) in gay bars Karyn Heavner, PhD 1, 2, James Tesoriero,
Current harm reduction program at outreach
Massachusetts Department of Public Health
Marie P. Bresnahan, MPH, Mary M
Amanda D. Castel, MD, MPH Assistant Research Professor
Utilization of New York State Syringe Exchange Programs:
National Hepatitis Coordinators’ Conference January 26 – 30, 2003
Sherry Deren, Sung-Yeon Kang, Milton Mino & Honoria Guarino
Table 1: NHBS HET3 Participant Characteristics
Evaluating a HIV Prevention Program AMONG People Who Inject Drugs in Southwest China Using Coarsened Exact Matching (CEM) Kai Wang Hongyun Fu Kim Longfield.
Believed discrimination occurred because of their:
No one gets left behind: Addressing the hidden burden of hepatitis C related advanced liver disease in PWID in the community John S Lambert, MD, PhD.
Blinded Hepatitis C Antibody Serosurvey among clients using the Wisconsin HIV Counseling, Testing, and Referral Program Angela Russell, MS John Pfister,
Hepatitis B and C management pathways in prison:
Summary Report: Management of Hepatitis C in Prisons
Viral Hepatitis in Correctional Settings
Community Intervention Strategies
Bloodborne viral and sexually transmissible infections in Aboriginal and Torres Strait Islander people Annual Surveillance Report 2017.
Expanding the Universe of Viral Hepatitis Treaters
Past 30-Day Marijuana Use Categories
Providing Guidance For Early Identification, Enhance Testing, and Fast Tracking to Care EIIHA Pilot Projects.
Viral Hepatitis Prevention Project (VHPP) in Massachusetts
More Than Treatment.
HCV Screening.
STIs in a multi-site sample of high-risk, substance-using MSM:
FACTORS ASSOCIATED WITH RECEIPT OF HEPATITIS B VACCINE AMONG HIGH RISK ADULTS NATIONAL HEALTH INTERVIEW SURVEY, 2000 Nidhi Jain MD MPH The topic of my.
Hepatitis B Vaccination Assessment Adults Aged Years National Health Interview Survey, 2000 Gary L. Euler, DrPH1, Hussain Yusuf, MBBS2, Shannon.
Progress in Facilitating National HCV Prevention
The relationship between incarceration and opioid addiction treatment
Florida International University
Lesson 3: Treatment as Prevention
Share your thoughts on this presentation with #IAS2019
March 8, 2006 New ACIP Hepatitis B Recommendations
Presentation transcript:

Attitudes, Testing and Treatment Rates of Hepatitis C and HIV Among Injection Drug Users Rowe, KA1, Tesoriero, JM1, Davis, SJ1, Heavner, KK1, Rothman, J2, Litwin, AH3, Slifer, M1, Birkhead, GS1 1New York State Department of Health, AIDS Institute. 2New York State Department of Health, Bureau of Project Management. 3Albert Einstein College of Medicine and Montefiore Medical Center, Bronx, NY.

Background Globally, an estimated 180 million persons are chronically infected with the hepatitis C virus (HCV) and 3 to 4 million persons are newly infected each year. There are approximately 4.1 million Americans estimated to be infected with HCV. In the U.S., nearly 90% of individuals newly diagnosed with HCV have a history of injection drug use (IDU).

Background (continued…) IDU is also among the leading risk factors for HIV/AIDS in the U.S. and accounts for just under one-third of new HIV infections outside of sub-Saharan Africa. Currently about 1 million Americans are infected with HIV and 300,000 Americans are co-infected with HIV and HCV.

Background (continued…) There are approximately 170,000 active IDUs in New York State; 125,000 active IDUs reside in New York City. IDUs are at increased risk for contracting both HIV and HCV.

Background (continued…) Historically IDUs have had less access to HCV evaluation and treatment than to HIV related services. For example, in many syringe exchange programs (SEPs) and methadone maintenance treatment programs (MMTPs) few hepatitis services exist and if services do exist, HCV treatment is seldom utilized.

Viral Hepatitis Integration Project (VHIP) Five year grant from CDC that began October 2004 (CDC Grant #U50/CCU224192). VHIP seeks to integrate hepatitis screening, testing, prevention and treatment into drug treatment and substance use settings that already provide HIV services to clients.

VHIP Sites in New York City Two SEPs (both have multiple sites) One MMTP (multiple sites) Note: many types of services are typically offered in both SEPs and MMTPs (for example, HIV testing, support groups, outreach, counseling, case management, etc.)

VHIP Services - SEPs Services available on-site: Hepatitis coordinator HBV and HCV screenings HAV and HBV vaccinations HCV evaluation and treatment referrals Support groups Hepatitis educational materials

VHIP Services - MMTPs Enhancement of services: Hepatitis coordinator & hepatitis educator On-site evaluation and treatment for HCV+ clients Support groups and peer education Hepatitis educational materials

VHIP Primary Evaluation Activities Client Survey (baseline/follow-up) Medical Staff Survey (baseline/follow-up) Non-Medical Staff Survey (baseline/follow-up) Hepatitis Service Tracking System (ongoing) Educational Materials (ongoing) Focus Groups (ongoing)

Methods Baseline Client Survey In-person 20 minute interview administered by the hepatitis coordinators or the hepatitis educator. Administered in English at the MMTP and in English and Spanish at the SEPs. Recruitment - Active recruitment - Passive recruitment $10 incentive (subway fare).

Instrument Baseline Client Survey Knowledge of Hepatitis & HIV Risks Attitudes Towards Hepatitis and HIV Prevention Experiences with Hepatitis and HIV Testing and Prevention Hepatitis and HIV Risk Awareness of Hepatitis and HIV Educational Materials

Description of Participants SEPs (n=617) MMTP (n=797) Total (n=1414) Mean Age (n) 41.3 (604) 45.0 (788) 43.4 (1392) Gender1(n) Male Female (609) 70.9% 28.1% (778) 50.0% 49.6% (1387) 59.2% 40.2% Race/Ethnicity (n) Hispanic Non-Hispanic, Black Non-Hispanic, White Non-Hispanic, Other (612) 66.8% 26.5% 4.7% 2.0% (785) 62.7% 26.6% 6.9% 3.8% (1397) 64.5% 5.9% 3.0% 1p<0.0001.

Hepatitis C/HIV Status1 SEPs (n=420) MMTP (n=560) Total (n=980) HCV+/HIV-2 52.4% 42.9% 46.9% HCV+/HIV+3 10.5% 18.4% 15.0% HCV-/HIV+ 6.2% 5.0% 5.5% HCV-/HIV- 40.0% 33.8% 32.6% 1Limited to clients who were ever tested for HCV and/or HIV and know the result of each test, 2p<.01, 3p<.001.

Knowledge of Hepatitis SEPs (n=617) MMTP (n=791) Total (n=1408) The best way to prevent HBV is by getting vaccinated (true)1 78.9% 64.6% 70.9% The best way to prevent HCV is by getting vaccinated (false)2 40.8% 32.0% 35.9% People who have both HIV and HCV cannot be treated for HCV (false)3 63.6% 55.5% 59.1% Everyone with HCV needs treatment (false) 22.0% 19.0% 20.3% p<.0001, p<.001, p<.01.

Knowledge of Hepatitis (continued…) SEPs (n=617) MMTP (n=791) Total (n=1408) Mean % of 12 questions answered correctly1 66.2% 53.7% 59.2% 1p<.0001.

Attitudes and Beliefs Regarding Hepatitis1 SEPs (n=617) MMTP (n=791) Total (n=1408) I would agree to get hepatitis vaccines.2 95.0% 88.9% 91.6% I would get a liver biopsy if my health care provider recommended it.3 93.2% 92.3% I would take HCV treatment if my health care provider recommended it.3,4 95.1% 88.0% 91.1% I would rather deal with the side effects of HCV treatment than have HCV.3,5 81.6% 69.8% 74.9% 1Clients who either “agreed” or “strongly agreed” with the statement. 2p<0.0001, 3Limited to HCV+ clients (n~610), 4p<0.01, 5p<.001.

Self-Reported Testing History 98% 73% 58% 56%

Self-Reported Positivity Rates1 60% 21% 18% 14% 1Limited to clients who were ever tested.

HCV Testing and Status History SEPs (n=615) MMTP (n=790) Total (n=1405) Ever Tested for HCV1 Yes 73.5% 73.0% 73.2% No 18.7% 8.1% 12.7% Unknown 7.8% 18.9% 14.0% Self-Reported HCV Status2,3 HCV Positive 59.0% 60.1% 59.7% HCV Negative 35.0% 38.1% 36.7% 6.0% 1.7% 3.6% 1p<0.0001, 2Limited to clients who were ever tested, 3p<0.001.

HIV Testing and Status History SEPs (n=615) MMTP (n=788) Total (n=1403) Ever Tested for HIV Yes 98.2% 97.2% 97.6% No 1.6% 1.8% 1.7% Unknown 0.2% 1.0% 0.6% Self-Reported HIV Status1,2 HIV Positive 14.7% 20.8% 18.1% HIV Negative 84.3% 78.7% 81.2% 0.5% 0.7% 1Limited to clients who were ever tested, 2p<0.001.

HAV Testing and Vaccination History SEPs (n=614) MMTP (n=784) Total (n=1398) Ever Tested for Hepatitis A1 Yes 55.7% 56.8% 56.3% No 27.2% 12.1% 18.7% Unknown 17.1% 31.1% 25.0% Hepatitis A Positive2 14.9% 12.6% 13.6% Ever Vaccinated for Hepatitis A1 36.2% 32.8% 34.3% 49.1% 23.5% 34.7% 14.6% 43.7% 31.0% 1p<0.0001, 2Limited to clients who were ever tested.

HBV Testing and Vaccination History SEPs (n=614) MMTP (n=785) Total (n=1399) Ever Tested for Hepatitis B1 Yes 61.6% 55.2% 58.0% No 23.6% 12.4% 17.3% Unknown 14.8% 32.5% 24.7% Hepatitis B Positive2,3 24.3% 17.8% 20.8% Ever Vaccinated for Hepatitis B1 39.4% 31.9% 35.2% 46.9% 23.2% 33.5% 13.7% 44.9% 31.3% 1p<0.0001, 2Limited to clients who were ever tested, 3p<0.05.

Why Not Tested/Vaccinated? Most commonly reported reasons for not getting tested and/or vaccinated for hepatitis A, B and/or C included: -not knowing should be tested/ vaccinated, -not being offered testing/vaccination, -not knowing about hepatitis or that testing/vaccinations were available.

Drug Use Behaviors SEPs MMTP Total Ever Injected Drugs1 64.9% 57.0% 60.4% Injected Drugs in the Past 12 Months2 40.2% 17.2% 27.2% Took Methadone in the Past 12 Months2 61.2% 99.8% 83.0% 1p<0.01, 2p<0.0001.

Drug Use Behaviors by Gender Male (n=814) Female (n=553) Ever Injected Drugs1 63.8% 54.7% Injected Drugs in the Past 12 Months2 32.8% 18.7% Took Methadone in the Past 12 Months2 79.5% 88.1% 1p<0.001, 2p<0.0001.

Drug Use Behaviors by Race/Ethnicity Hispanic (n=894) Black (n=367) White (n=83) Ever Injected Drugs1 62.6% 51.1% 75.9% Injected Drugs in the Past 12 Months1 31.4% 15.3% 38.3% Took Methadone in the Past 12 Months2 83.8% 77.6% 91.6% 1p<0.0001, 2p<0.01.

Drug Use Behaviors Odds Ratios (95% C.I.)1 HCV+ (n=460)2 HIV+ (n=54)2 HCV+/ (n=146)2 Ever Injected Drugs 14.73 (10.5, 20.5) 1.74 (1.3, 2.4) 4.53 (2.6, 7.9) Injected Drugs in Past 12 Months 3.13 (2.2, 4.2) 0.8 (0.5, 1.1) (0.5,1.2) Took Methadone Past 12 Months (2.1, 4.4) 1.2 (0.8, 1.8) 2.05 (1.1, 3.7) 1C.I.=confidence intervals, 2Limited to clients who were ever tested, 3p<.0001, 4p<0.001, 5p<0.05.

HCV+ Client Treatment Readiness 76% discussed treatment with a health care provider. 62% stated they were ready for treatment now or in the near future. 30% decreased alcohol consumption after HCV diagnosis.

Intentions versus Behavior HCV+ Clients (n=460) 92% 91% 22% 15%

Treatment Rates HCV+ and HIV+ Clients 82% 17% 15% 10%

Conclusions Moderately knowledgeable about hepatitis. Favorable attitudes toward hepatitis testing, vaccinations and treatment. Clients in SEP and MMTP settings have higher rates of HCV than HIV. Hepatitis services are accessed at much lower rates than HIV services.

Conclusions (continued…) Hepatitis vaccinations and testing should be encouraged among this population. Increasing access to hepatitis education, vaccinations, testing and treatment services should also be made readily available to this population.

Conclusions (continued…) Make sure clients understand what they are being tested and/or vaccinated for. Follow-up with clients to ensure they receive and understand their test results. SEPs and MMTP clinics are ideal settings to provide education and implement hepatitis testing, vaccinations and services for clients.

Acknowledgements Collaborating Partners: New York Harm Reduction Educators St. Ann’s Corner of Harm Reduction Albert Einstein College of Medicine

Information Kirsten Rowe Office of Program Evaluation and Research New York State Department of Health AIDS Institute Riverview Center - 150 Broadway - Suite 516 Menands, NY 12204 kas11@health.state.ny.us (518) 402-6814